1. Home
  2. VSAT vs CNTA Comparison

VSAT vs CNTA Comparison

Compare VSAT & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ViaSat Inc.

VSAT

ViaSat Inc.

HOLD

Current Price

$63.85

Market Cap

5.6B

Sector

Technology

ML Signal

HOLD

Logo Centessa Pharmaceuticals plc

CNTA

Centessa Pharmaceuticals plc

HOLD

Current Price

$39.54

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSAT
CNTA
Founded
1986
2020
Country
United States
United Kingdom
Employees
N/A
118
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.1B
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
VSAT
CNTA
Price
$63.85
$39.54
Analyst Decision
Strong Buy
Buy
Analyst Count
6
9
Target Price
$51.40
$42.00
AVG Volume (30 Days)
1.6M
5.0M
Earning Date
05-19-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
50.88
29.13
EPS
N/A
N/A
Revenue
N/A
$15,000,000.00
Revenue This Year
$5.34
N/A
Revenue Next Year
$3.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.95
$10.95
52 Week High
$64.46
$40.26

Technical Indicators

Market Signals
Indicator
VSAT
CNTA
Relative Strength Index (RSI) 72.10 74.75
Support Level $42.18 $39.16
Resistance Level N/A $40.26
Average True Range (ATR) 3.59 0.32
MACD 1.11 -0.10
Stochastic Oscillator 95.31 34.09

Price Performance

Historical Comparison
VSAT
CNTA

About VSAT ViaSat Inc.

Viasat Inc provides bandwidth technologies and services in three segments: communication services and defense and advanced technologies. The communication services segment provides a wide range of broadband and narrowband communications solutions across government and commercial mobility markets, as well as for residential and enterprise fixed broadband customers: and the defense and advanced technologies segment develops and offers a diverse array of resilient, vertically integrated solutions to government and commercial customers, leveraging core technical competencies in encryption, cyber security, tactical gateways, modems and waveforms. A large majority of the firm's revenue is generated from communication services segment.

About CNTA Centessa Pharmaceuticals plc

Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.

Share on Social Networks: